FINWIRES · TerminalLIVE
FINWIRES

研究快訊:Nokia:2026年第一季業績符合預期,光網路實力強勁,人工智慧需求支撐成長

-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下:Nokia2026年第一季業績符合預期,可比淨利為2.95億歐元(年成長93%),營業利潤為2.81億歐元(年成長54%),佔2026年預期值的17%。營收達45億歐元(以固定匯率計算年增4%),主要得益於人工智慧相關需求的成長,但電信業務疲軟和匯率波動抵消了部分成長。網路基礎設施業務推動成長,營收成長6%至18億歐元,其中光網路業務成長20%至8.21億歐元,主要得益於超大規模資料中心和人工智慧的需求;行動基礎設施業務溫和成長3%至25億歐元,營業利潤率提升380個基點至8.9%。管理層維持2026年全年可比營業利潤預期為20億至25億歐元,並將網路基礎設施成長預期從6%-8%上調至12%-14%,反映出人工智慧和雲端運算發展勢頭強勁。我們認為,人工智慧驅動的需求將繼續支撐這一前景,預計利潤率將逐步擴大,但業績仍與電信資本支出復甦和區域需求波動(尤其是在北美)密切相關。

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF